184970-28-3

Basic information

• Product Name: 4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE
• Synonyms: 4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE;4-Bromo-2-bromomethylanisole
• CAS NO: 184970-28-3
• Molecular Formula: C₈H₈Br₂O
• Molecular Weight: 279.96
• Mol File: 184970-28-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE(184970-28-3)
• EPA Substance Registry System: 4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE(184970-28-3)

Safety Data

• Hazardous Substances Data: 184970-28-3(Hazardous Substances Data)

Usage

General Description

4-Bromo-2-(bromomethyl)-1-methoxybenzene is a chemical compound with a molecular formula of C8H8Br2O. It's an aromatic organic compound that belongs to the benzene and substituted derivatives group. 4-BROMO-2-(BROMOMETHYL)-1-METHOXYBENZENE mainly contains two bromine atoms; one at the fourth carbon and the other on the methylene carbon, and a methoxy group attached on the first carbon of the benzene ring. Its properties such as melting point, boiling point, density, or toxicity are not typically listed in most sources, suggesting that it's not widely used or that studies have been limited. Information on this compound may require further research due to limited available data.

Upstream product

• 14804-31-0 2-methyl-4-bromoanisole 
• 80866-82-6 5-bromo-2-methoxy-benzyl alcohol 

Downstream Products

• 88857-57-2 2-<2-(5-Brom-2-methoxy-phenyl)-ethyl>-benzoesaeure 
• 954123-89-8 tert-butyl 4-((5-bromo-2-methoxybenzyloxy)methyl)-4-phenylpiperidine-1-carboxylate 
• 144649-99-0 5-bromo-2-methoxybenzonitrile 
• 40530-18-5 5-bromo-2-hydroxybenzonitrile 
• 876918-26-2 5-bromo-2-isobutoxy-benzonitrile 
• 1139901-88-4 tert-butyl 2-(3’-cyano-4’-isobutoxyphenyl)-4-methylthiazole-5-carboxylate 
• 144060-53-7 febuxostat 
• 24523-97-5 ethyl 2-(5-bromo-2-methoxybenzyl)-3-oxobutanoate 
• 24524-13-8 5-(5-bromo-2-methoxybenzyl)-4-chloro-6-methylpyrimidin-2-amine 
• 24524-08-1 2-amino-5-(5-bromo-2-methoxybenzyl)-6-methylpyrimidin-4-ol 
• 25016-01-7 5-bromo-2-methoxybenzaldehyde 
• 1331750-46-9 tert-butyl 2-(N-(5-bromo-2-methoxybenzyl)-2,2-dimethylchroman-6-sulfonamido)acetate 
• 68592-15-4 methylhonokiol 

Relevant articles and documents

Synthesis and Evaluation of Europium Complexes that Switch on Luminescence in Lysosomes of Living Cells

A set of four luminescent EuIII complexes bearing an extended aryl-alkynylpyridine chromophore has been studied, showing very different pH-dependent behaviour in their absorption and emission spectral response. For two complexes with pKa/

One-pot transformation of methylarenes into aromatic aldehydes under metal-free conditions

On the basis of studies of the transformation of benzylic bromides into the corresponding aromatic aldehydes by treatment with N-methylmorpholine N-oxide, various methylarenes were treated either with DBDMH in the presence of AIBN in acetonitrile at reflux (Method A) or with NBS in CCl4 under irradiation with a tungsten lamp at 30 °C (Method B), followed by treatment with N-methylmorpholine N-oxide to provide aromatic aldehydes in good yields. These methods could be adopted in one-pot transformations of methylarenes into aromatic aldehydes under conditions free of less toxic reagents and transition metals. Copyright

TRIAZOLONE COMPOUNDS AND USES THEREOF

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.